Sr. Director - Global Diagnostics Environment

Chester, Maryland, United States

Auto‑apply with AI Apply

Not SpecifiedCompensation

Senior (5 to 8 years)Experience Level

Full TimeJob Type

UnknownVisa

Pharmaceuticals & BiotechnologyIndustries

Requirements

Candidates should possess a Bachelor’s degree and a minimum of 4 years of relevant experience working with external partners in Corporate Affairs, External Affairs, or a Society leadership role, or equivalent experience. Qualified applicants must be authorized to work in the United States on a full-time basis.

Responsibilities

The Sr. Director - Global Diagnostics Environment will function as the global expert leader on diagnostic consortia, coalitions, and industry groups across the company, creating and owning the strategic approach for working with these groups to advance Lilly’s patient identification goals. This leader will also lead the engagement of key global diagnostic groups and their leadership, deliver strategic plans for prioritized collaboration, manage global pathology and lab conferences, survey and monitor diagnostic-related industry activity, present at global conferences, consolidate insights from the diagnostic environment, collaborate with Scientific Affairs and Corporate/Government Affairs teams, and ensure Dx Environment solutions are integrated into Innovation and Launch Readiness planning.

Skills

Diagnostic industry knowledge

Strategic planning

Stakeholder engagement

Global diagnostic ecosystem understanding

Laboratory medicine

Industry collaboration

Leadership in consortia and coalitions

Eli Lilly and Company

Develops and delivers prescription medicines globally

About Eli Lilly and Company

Eli Lilly and Company is a global pharmaceutical company that focuses on discovering, developing, and delivering medicines to improve health. The company has a long history of scientific achievements, including the creation of insulin, the first life-saving treatment for diabetes. Lilly's operations involve extensive research and development to create new medications and enhance existing ones, ensuring they are safe and effective. Their products are primarily prescription medicines sold to healthcare providers for various medical conditions, including diabetes, cancer, and pain management. What sets Lilly apart from its competitors is its strong commitment to ethical practices and the protection of its products from counterfeiting. The company's goal is to enhance lives through innovative medical solutions while maintaining high standards of quality and ethics.

Indianapolis, IndianaHeadquarters

1876Year Founded

$1,180.1MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

10,001+Employees

Risks

Competition from Novo Nordisk's Ozempic may impact tirzepatide's market share.

Potential construction delays in Indiana could affect GLP-1 drug production timelines.

Regulatory challenges may hinder Kisunla's expansion in new Alzheimer's markets.

Differentiation

Eli Lilly's rich history includes the first life-saving insulin treatment.

Lilly's strategic partnerships enhance its position in neurodegenerative disease treatments.

FDA approval of Zepbound opens new therapeutic markets for sleep disorder treatments.

Upsides

Lilly's $9 billion complex in Indiana boosts GLP-1 drug production capacity.

Kisunla's approval in China expands Lilly's Alzheimer's treatment market in Asia.

Collaboration with EVA Pharma enhances Lilly's reputation as socially responsible.

Land your dream remote job 3x faster with AI

Try Jobo Free